Pembrolizumab Therapy in a Patient with NSCLC and Bullous Pemphigoid: A Case Report

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Aug 14

PMID 39139747

Authors

Ang Li

Fasheng Li

Zhipeng Ma

Yutao Pang

Boyun Deng

Zhan He

Zhu Liang

Jie Chen

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitor (ICI) therapy, which targets programmed cell death protein 1, has demonstrated enhanced survival outcomes in numerous patients with cancer. Historically, individuals with autoimmune diseases have been excluded from clinical trials involving cancer immunotherapies due to concerns about the potential worsening of their underlying autoimmune conditions. In the present case report, a patient with non-small cell lung cancer and bullous pemphigoid (BP) who underwent treatment with the ICI pembrolizumab is described. In this specific clinical case, no severe exacerbation of the underlying autoimmune disease was observed. Contrarily, the patient not only tolerated pembrolizumab well but also experienced amelioration of the BP lesions after the treatment. This case challenges the conventional exclusion criteria for ICI therapy in patients with autoimmune diseases, suggesting the potential safety and efficacy of such treatments in this specific population. However, further investigations and larger-scale studies are warranted to validate these findings and provide a more comprehensive understanding of the implications of ICI therapy in patients with autoimmune comorbidities.

References

Reckamp K, Redman M, Dragnev K, Minichiello K, Villaruz L, Faller B . Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022; 40(21):2295-2306. PMC: 9287284. DOI: 10.1200/JCO.22.00912. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Moro F, Fania L, Sinagra J, Salemme A, Di Zenzo G . Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules. 2020; 10(10). PMC: 7600534. DOI: 10.3390/biom10101432. View

Tison A, Quere G, Misery L, Funck-Brentano E, Danlos F, Routier E . Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol. 2019; 71(12):2100-2111. DOI: 10.1002/art.41068. View

Kaul S, Wang A, Grushchak S, Albrecht J . Pembrolizumab-induced reactivation of bullous pemphigoid. Int J Dermatol. 2021; 60(6):757-758. DOI: 10.1111/ijd.15366. View

Balestri R, Magnano M, La Placa M, Patrizi A, Angileri L, Tengattini V . Malignancies in bullous pemphigoid: A controversial association. J Dermatol. 2015; 43(2):125-33. DOI: 10.1111/1346-8138.13079. View

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

Hammers C, Stanley J . Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. Annu Rev Pathol. 2016; 11:175-97. PMC: 5560122. DOI: 10.1146/annurev-pathol-012615-044313. View

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

10.

Md Radzi A, Kasim S . A case report of paraneoplastic bullous pemphigoid associated with mantle cell lymphoma: A rare presentation. Medicine (Baltimore). 2023; 102(4):e32822. PMC: 9875989. DOI: 10.1097/MD.0000000000032822. View

11.

Das A, Das S, Das S, Basuthakur S . A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung. J Postgrad Med. 2015; 61(3):197-9. PMC: 4943416. DOI: 10.4103/0022-3859.150906. View

12.

Leonardi G, Gainor J, Altan M, Kravets S, Dahlberg S, Gedmintas L . Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018; 36(19):1905-1912. PMC: 6553840. DOI: 10.1200/JCO.2017.77.0305. View

13.

Lucariello R, Villablanca S, Mascaro Jr J, Reichel M . Association between bullous pemphigoid and malignancy: A meta-analysis. Australas J Dermatol. 2018; 59(4):253-260. DOI: 10.1111/ajd.12764. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J . Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. J Thorac Oncol. 2021; 16(7):1099-1117. DOI: 10.1016/j.jtho.2021.03.016. View

16.

Boutros C, Tarhini A, Routier E, Lambotte O, Leroy Ladurie F, Carbonnel F . Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473-86. DOI: 10.1038/nrclinonc.2016.58. View

17.

Dafni U, Tsourti Z, Vervita K, Peters S . Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 2019; 134:127-140. DOI: 10.1016/j.lungcan.2019.05.029. View

18.

Arbour K, Mezquita L, Long N, Rizvi H, Auclin E, Ni A . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(28):2872-2878. DOI: 10.1200/JCO.2018.79.0006. View

19.

Albadri Z, Thorslund K, Habel H, Seifert O, Gronhagen C . Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study. Acta Derm Venereol. 2020; 100(17):adv00289. PMC: 9274914. DOI: 10.2340/00015555-3622. View

20.

Doroshow D, Sanmamed M, Hastings K, Politi K, Rimm D, Chen L . Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019; 25(15):4592-4602. PMC: 6679805. DOI: 10.1158/1078-0432.CCR-18-1538. View